red_moon_rise In my previous Gritstone bio (NASDAQ:GRTS) article, I discussed how the company’s technology could make it a cutting-edge infectious disease firm with a strong list of collaborations that could rival Moderna (MRNA) and BioNTech (BNTX). However, I also noted that the company’s biggest upside potential was its oncology programs, notably GRANITE, which could transform…
phuttaphat tipsana/iStock via Getty Images Thesis overview Evaxion (EVAX) aspires to use artificial intelligence (AI) to design vaccines for cancer immunotherapy, as well as for infectious diseases. EVAX claims being more advanced than competition because it has been constantly developing and improving its models for 15 years. Additionally, EVAX has in-house capability to validate novel…
Maskot/DigitalVision via Getty Images Investment Overview Moderna, Inc. (NASDAQ:MRNA) held an investor event today to review its vaccines program and provide key business updates. Before we dive into that, let’s quickly review recent performance. The company announced its Q4 and full year 2023 earnings and business updates on February 22nd. Moderna described 2023 as a…
Leon Neal GSK overview GSK plc (NYSE:GSK) is a British multinational “Big Pharma” established in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham. It possesses a leading position in the traditional vaccine (Not mRNA vaccine) and HIV area. In fact, GSK produced the first FDA-approved malaria vaccine. Currently, its best-selling vaccine is Shingrix…
Jelena Stanojkovic/iStock via Getty Images At a Glance Delving into Moderna’s (NASDAQ:MRNA) trajectory, my earlier analysis shed light on its eclectic project range. This spectrum spans from oncology to infectious diseases, with notable breakthroughs in RSV and flu vaccines. Moderna has since leaped forward, especially with mRNA-1083. This vaccine, both innovative and dual-purpose, targets COVID-19…
hapabapa Moderna (NASDAQ:MRNA) and Merck (MRK) reported data regarding their cutting-edge mRNA-based skin cancer regimen that includes the former’s cancer vaccine, MRNA-4157. The companies recently reported promising results from a Phase II trial, demonstrating the vaccine’s efficacy in treating melanoma. The data revealed a noteworthy 49% reduction in the possibility of cancer recurrence or death…
The updated vaccine specifically addresses the XBB.1.5 subvariant of the Omicron variant, which has raised concerns due to its potential to evade immunity conferred by earlier versions of the vaccine. In a recent development, stocks of Novavax Inc (NASDAQ: NVAX) jumped 8.2% yesterday following the Food and Drug Administration’s (FDA) approval of its improved COVID-19…
Natali_Mis/iStock via Getty Images Certain medicines are so widely necessary that it is impossible to charge too much for them. Antibiotics and vaccines fall under this class. I never buy vaccine stocks, barring the rare exception, because I believe ROI may be poor for such companies. With that caveat, let us dig into HilleVax (NASDAQ:HLVX),…
Covid vaccine stocks, including Moderna, BioNTech, and Novavax have all closed higher as new vaccinations and treatments roll out. Makers of Covid vaccines had their stocks climb on Monday following reports that new variants were discovered in the United States. The rise in these stocks coincides with preparation for new immunization sensitization as new Covid…